MXPA06012980A - Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea. - Google Patents

Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.

Info

Publication number
MXPA06012980A
MXPA06012980A MXPA06012980A MXPA06012980A MXPA06012980A MX PA06012980 A MXPA06012980 A MX PA06012980A MX PA06012980 A MXPA06012980 A MX PA06012980A MX PA06012980 A MXPA06012980 A MX PA06012980A MX PA06012980 A MXPA06012980 A MX PA06012980A
Authority
MX
Mexico
Prior art keywords
mucosal delivery
methods
parathyroid hormone
compositions
enhanced mucosal
Prior art date
Application number
MXPA06012980A
Other languages
English (en)
Inventor
Steven C Quay
Mary S Kleppe
Henry R Constantino
Ching-Yuan Li
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of MXPA06012980A publication Critical patent/MXPA06012980A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen composiciones y metodos farmaceuticos que comprenden al menos un peptido de hormona paratifoidea (PTH) preferentemente PTH1-34 y uno o mas agentes que mejoran el suministro mucosal para mejorar el suministro mucosal nasal de PTH, para tratar o prevenir la osteoporosis u osteopenia en un sujeto mamifero, preferentemente un humano.
MXPA06012980A 2004-05-10 2005-05-10 Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea. MXPA06012980A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57011304P 2004-05-10 2004-05-10
PCT/US2005/016530 WO2005115441A2 (en) 2004-05-10 2005-05-10 Compositions and methods for enhanced mucosal delivery of parathyroid hormone

Publications (1)

Publication Number Publication Date
MXPA06012980A true MXPA06012980A (es) 2007-06-12

Family

ID=35207584

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06012980A MXPA06012980A (es) 2004-05-10 2005-05-10 Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.

Country Status (9)

Country Link
US (6) US7244709B2 (es)
EP (1) EP1750756A2 (es)
JP (1) JP2007537274A (es)
CN (1) CN101151048A (es)
AU (1) AU2005247369A1 (es)
CA (1) CA2567056A1 (es)
MX (1) MXPA06012980A (es)
RU (1) RU2006143544A (es)
WO (1) WO2005115441A2 (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
US20040176476A1 (en) * 2001-06-22 2004-09-09 Gyurik Robert J. Pharmaceutical composition
CA2567056A1 (en) * 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
AU2006252342A1 (en) * 2005-06-02 2006-12-07 Alza Corporation Method for terminal sterilization of transdermal delivery devices
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
EP1893240A2 (en) * 2005-06-13 2008-03-05 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
JP2009502967A (ja) * 2005-07-27 2009-01-29 ナステック ファーマスーティカル カンパニー インク． 粘膜送達を向上させるためのタイトジャンクション調節ペプチド化合物
AU2006299887A1 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. PTH formulations and methods of use
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
WO2007059470A2 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2007106597A2 (en) * 2006-03-15 2007-09-20 Alza Corporation Method for the transdermal delivery of parathyroid hormone agents for treating osteopenia
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US20090326193A1 (en) * 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) * 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP2049149B1 (en) * 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
EP2046284A1 (en) * 2006-08-04 2009-04-15 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
HUE029512T2 (en) * 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
MX2009003569A (es) * 2006-10-03 2009-08-25 Radius Health Inc Metodo de administracion de farmacos para la proteina anabolica osea.
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
WO2008065144A2 (en) * 2006-11-29 2008-06-05 Novartis Ag Galenic formulations of organic compounds
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
JP5496082B2 (ja) * 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
EP2514406A1 (en) * 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
EP2164458A1 (en) * 2007-06-01 2010-03-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
WO2009100216A1 (en) * 2008-02-08 2009-08-13 Qps Llc Composition for sustained release delivery of proteins or peptides
WO2009112583A2 (en) * 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
EP2271347B1 (en) 2008-03-28 2016-05-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
NZ590256A (en) * 2008-07-11 2013-03-28 Map Pharmaceuticals Inc INHALER CANISTER WITH PRIMELESS VALVE AND VOLUME LESS THAN 10mL
CA2733514C (en) * 2008-08-21 2017-10-24 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
ES2606546T3 (es) * 2009-02-11 2017-03-24 Heglund, A.S. Compuesto destinado a la absorción bucal de nicotina con el objetivo de dejar de fumar
US20100256060A1 (en) * 2009-04-02 2010-10-07 Unigene Laboratories Inc. Peptide pharmaceuticals for nasal delivery
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
ES2843649T3 (es) * 2009-09-09 2021-07-20 Asahi Kasei Pharma Corp Agente terapéutico/profiláctico que contiene PTH para la osteoporosis, caracterizado porque la PTH se administra una vez por semana en una dosis unitaria de 200 unidades
BR112012009801A8 (pt) 2009-10-30 2016-08-30 Cns Therapeutics Inc Polipeptídeo neurturina e variante de neurturina
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
AU2011316111B2 (en) 2010-10-12 2015-05-28 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
WO2013176054A1 (ja) * 2012-05-25 2013-11-28 ライオン株式会社 アスコルビン酸誘導体を含む剤およびその用途
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
WO2015052088A1 (en) 2013-10-07 2015-04-16 Novo Nordisk A/S Novel derivative of an insulin analogue
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
AU2016256470B2 (en) 2015-04-29 2020-10-15 Radius Pharmaceuticals, Inc. Methods of treating cancer
CN115025239A (zh) 2016-03-01 2022-09-09 阿森迪斯药物骨疾病股份有限公司 Pth前药
WO2018060310A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release pth compound
ES2943720T3 (es) 2016-09-29 2023-06-15 Ascendis Pharma Bone Diseases As Compuestos de PTH con bajas relaciones de pico a valle
HRP20221324T1 (hr) 2016-12-16 2022-12-23 Novo Nordisk A/S Farmaceutski pripravci koji sadrže inzulin
LT3565542T (lt) 2017-01-05 2024-07-10 Radius Pharmaceuticals, Inc. Polimorfinės rad1901-2hcl formos
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
WO2019059302A1 (ja) * 2017-09-22 2019-03-28 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
AU2017432640B2 (en) 2017-09-22 2023-11-30 Vectura Inc. Dry powder compositions with magnesium stearate
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN111163827A (zh) * 2017-11-27 2020-05-15 丽年控股有限公司 汽化器系统
EP3793587A1 (en) * 2018-05-18 2021-03-24 Ascendis Pharma Bone Diseases A/S Starting dose of pth conjugates
US20210251886A1 (en) * 2018-06-10 2021-08-19 Zim Laboratories Limited Oral mucosal delivery systems comprising monophasic concentrate of teriparatide
CN112423844B (zh) 2018-07-04 2024-08-13 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
CN109133356B (zh) * 2018-09-12 2021-09-14 浙江海洋大学 一种利用滤食生物除藻的方法
SG11202107722VA (en) * 2019-02-11 2021-08-30 Ascendis Pharma Bone Diseases As Liquid pharmaceutical formulations of pth conjugates
US20230149295A1 (en) * 2020-03-09 2023-05-18 University Of Houston System Inflammatory bowel disease stem cells, agents which target ibd stem cells, and uses related thereto
KR20230057404A (ko) * 2020-08-26 2023-04-28 실라 세라퓨틱 인크. 흡입 가능한 치료제
CN116253809A (zh) * 2023-04-19 2023-06-13 广州润虹医药科技股份有限公司 一种去除壳聚糖中内毒素的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE21633T1 (de) * 1981-06-04 1986-09-15 Pharmasol Corp Druckbehaelter mit abgabepumpe.
US4476116A (en) * 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
GB9020544D0 (en) 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
ATE150648T1 (de) 1990-11-26 1997-04-15 Robert R Recker Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth)
JPH05238929A (ja) 1992-02-27 1993-09-17 Sumitomo Pharmaceut Co Ltd 代謝性骨疾患治療用長期持続性製剤
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
DE69429603T2 (de) 1993-09-22 2002-08-14 Hisamitsu Pharmaceutical Co., Inc. Iontophoresematrix
US5599822A (en) 1995-06-06 1997-02-04 Eli Lilly And Company Methods for minimizing bone loss
EP1166796A3 (en) 1996-02-01 2002-03-06 Chugai Seiyaku Kabushiki Kaisha Agents for preventing and treating thrombocytopenia
JPH10130171A (ja) 1996-09-04 1998-05-19 Dot:Kk 経口投与用医薬組成物
IL132901A0 (en) * 1997-05-14 2001-03-19 Aventis Pharm Prod Inc Peptide parathyroid hormone analogs
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999031137A1 (en) * 1997-12-18 1999-06-24 Eli Lilly And Company Crystalline teriparatide
EP2311436A1 (en) 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilized protein crystals, formulations containing them and methods of making them
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US20030059376A1 (en) 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US20010043906A1 (en) * 1999-12-30 2001-11-22 Vlasselaer Peter Van gamma-IFN liquid-droplet aerosol and method
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
WO2002062294A2 (en) * 2001-02-02 2002-08-15 Lh Skin Care Llc Skin care product delivery system
US20050123509A1 (en) 2001-10-19 2005-06-09 Lehrman S. R. Modulating charge density to produce improvements in the characteristics of spray-dried proteins
US20030185762A1 (en) * 2002-03-22 2003-10-02 Cowan Siu Man L. Highly aqueous liquid carrier formulations
EP1539208A2 (en) * 2002-06-28 2005-06-15 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
EP1631308B1 (en) * 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
BRPI0414539B8 (pt) 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
US6941871B2 (en) * 2003-11-05 2005-09-13 Sidney Wayne Mauldin Faceted expansion relief perforating device
AU2004292954A1 (en) 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
EP1701714A2 (en) * 2004-01-07 2006-09-20 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
CA2567056A1 (en) * 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060052306A1 (en) 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060189533A1 (en) 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
US20060062758A1 (en) * 2004-09-21 2006-03-23 Nastech Pharmaceutical Comapny Inc. Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds

Also Published As

Publication number Publication date
US7244709B2 (en) 2007-07-17
RU2006143544A (ru) 2008-06-20
US20070244049A1 (en) 2007-10-18
US20050276843A1 (en) 2005-12-15
CN101151048A (zh) 2008-03-26
JP2007537274A (ja) 2007-12-20
WO2005115441A2 (en) 2005-12-08
EP1750756A2 (en) 2007-02-14
WO2005115441A3 (en) 2006-03-16
AU2005247369A1 (en) 2005-12-08
US7435720B2 (en) 2008-10-14
US20100184688A1 (en) 2010-07-22
US20070154401A1 (en) 2007-07-05
US20070167364A1 (en) 2007-07-19
CA2567056A1 (en) 2005-12-08
US20070154400A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
MXPA06012980A (es) Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
WO2005080433A3 (en) Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
BRPI0509991A (pt) aparelho de fornecimento em aerossol, métodos e composições para sistemas de respiração auxiliados por pressão
ZA200606153B (en) Intranasal administration of glucose-regulating peptides
EP1744683A4 (en) DEVICE AND METHOD FOR THE TRANSDERMAL DISTRIBUTION OF PARATHYROIDHORMONE AGENTS
AR056806A1 (es) Moleculas quimericas de anticuerpo rankl- pth/ pthrp
IL173152A0 (en) Transdermal hormone delivery system: compositions and methods
MX356295B (es) Análogos de péptido de la hormona de estimulación de alfa-melanocito.
EA201001801A1 (ru) Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
GEP20074231B (en) Calcitonin gene related peptide receptor antagonists
NZ576682A (en) METHOD OF DRUG DELIVERY FOR BONE ANABOLIC PROTEIN PARATHYROID HORMONE-RELATED PROTEIN (PTHrP)
DE602004030700D1 (de) Rekombinanter antikörper gegen humanen insulin-like growth factor
IL209855A (en) Polypeptide, an amino acid sequence encoded for this polypeptide, and the use of this polypeptide to prepare a drug for the treatment of acromegaly
IL159714A (en) Pharmaceutical composition for oral delivery comprising a fragment of parathyroid hormone and 5-cnac
UA92011C2 (ru) Облатка, содержащая стероидные гормоны
HRP20110273T1 (hr) Pripravak za transmukozni unos polipeptida
WO2003105772A3 (en) PARATHYROID HORMONE ANALOGS AND PARATHYROID HORMONE-RELATED PROTEIN AS BONE ANABOLIZING AGENTS
GB2446341A (en) Method and system for transdermal drug delivery
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
GB0228305D0 (en) Therapeutic composition for respiratory delivery
NO20065673L (no) Sammensetninger og fremgangsmater for forbedret mucosal levering av parathyroid hormon.
TW200509960A (en) Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
TW200612981A (en) Treatment of cardiomyopathy and of endothelial dysfunction
WO2007005320A3 (en) Methods of delivering corticotroph-derived glycoprotein hormone
WO2007005995A3 (en) Compositions for buccal delivery of human growth hormone

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: KYPHON SARL

FA Abandonment or withdrawal